Feature | May 13, 2013| Dave Fornell

ECMO May Become the pVAD of the Future

There is a growing trend in the use of small, portable extracorporeal membrane oxygenation (ECMO) systems for hemodynamic support. In years past, ECMO systems were a tool of the operating room, primarily for bypass surgery. Older systems required a perfusionist to watch the machine 24 hours a day while it was in operation. Today’s ECMOs use consoles that are much easier to use and do not require a full-time person to monitor. Also, as the technology has been miniaturized, simplified and now uses a percutaneous access system, ECMOs are being used outside the OR, including the cath lab, when a large amount of support is needed that cannot be provided by IABPs or pVADs. 

“These are definitely being put in the cath lab more and will see increasing use in the cath lab in the future ­— that will become the norm,” said Alan L. Gass, M.D., medical director, heart failure, heart transplantation and mechanical circulatory support, Westchester Heart and Vascular, and associate professor of medicine, New York Medical College. 

“We have seen that trend and we are helping drive it,” said Luca Lombardi, M.D., chief medical officer, Maquet Cardiovascular. “The technology has evolved tremendously over the past few years to reduce the trauma to the patient. Just 10 years ago we had to do a full surgical exposure to access the vessels, but today the external diameter of the canula is percutaneous, between 1.2 mm for pediatrics and up to 5 mm for adults.”

Gass has experience with both the Maquet CardioHelp and Thoratec CentriMag extracorporeal circulatory support devices. 

The CardioHelp is the world’s smallest circulatory and/or pulmonary support system, weighing just 22 pounds. It can be carried by one person and can be used inside or outside the hospital, including for patient transport. It offers an easy-to-use, touch-screen console interface and plug-and-play setup. Gass said the system offers 3 to 5 lpm of flow, so in patients who need more support than an IABP, he often uses this system as the next step up. 

“It’s a great little system with everything you need put into a small package,” Gass said. 

His only criticism of the CardioHelp is the inability to see if clots are forming in the oxygenator. 

The CentriMag pump is also very small, lightweight and easily transportable. Thoretec says the system can deliver up to 9.9 lpm of flow. The pump has no bearings, but instead uses magnetic levitation, which the vendor says reduced hemolysis (destruction of red blood cells) and the likelihood of mechanical pump failure. 

Related Content

News | Cath Lab| May 24, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions took place May 4-7, 2016
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study
News | Intravascular Imaging| May 20, 2016
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
clot, coronary thrombus, antiplatelet therapt, DAPT

An intravascular ultrasound (IVUS) image of a thrombus formed in a coronary artery.  While there are guidelines for antiplatelet therapy, there are still questions over the duration of such therapy. 

Feature | Antiplatelet and Anticoagulation Therapies| May 19, 2016 | Marianne Pop, Pharm.D., BCPS
There are many opinions on the duration of dual antiplatelet therapy (DAPT), highlighted at the 2016 American College
bioabsorbable vascular graft, children, feasibility study, Bakoulev Center Moscow, AATS 2016 meeting

Image courtesy of Bakoulev Scientific Center for Cardiovascular Surgery

News | Stent Grafts| May 18, 2016
Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the...
NeoChord, DS1000 System, FDA approval, U.S. pivotal trial
News | Heart Valve Technology| May 17, 2016
NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
Biotronik, Magmaris bioresorbable magnesium scaffold, BIOSOLVE-II Trial, 12-month results, EuroPCR 2016
News | Stents Bioresorbable| May 17, 2016
Biotronik presented 12-month data from the BIOSOLVE-II trial during a Hotline Session at EuroPCR 2016.

Biosensors' Biomatrix stent.

Feature | Stents| May 16, 2016
May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables Co
Overlay Init